Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. (Beixin Life) officially listed on the Sci-Tech Innovation Board on February 5, 2026, under the stock code "688712.SH," marking it as the first medical device company to successfully list under the new fifth set of standards since its restart and the first medical device company to list in 2024 [3]. Group 1: Company Overview - Beixin Life is the first domestic medical device company with a product portfolio that includes intravascular functional flow reserve (FFR) and intravascular ultrasound (IVUS) [3]. - The company has received investments from several well-known institutions, including Qiming Venture Partners, which led its Series C financing in 2020 and continued to support its development in Series D financing [4]. Group 2: Investment Insights - Qiming Venture Partners holds over 6% of Beixin Life's shares prior to the IPO, indicating its role as a major institutional investor [4]. - The firm has a strong interest in the cardiovascular and other medical device sectors, having a history of successful cases in these fields [4]. Group 3: Strategic Approach - Beixin Life's strategy focuses on building a robust product portfolio and company capabilities rather than merely pursuing rapid registration, emphasizing the creation of differentiated and competitive products [5]. - The company has maintained this strategy for over a decade, which has instilled confidence among shareholders [5]. Group 4: Future Expectations - Post-IPO, Beixin Life is expected to continue strengthening its product line in the coronary field and expand into high-potential new areas such as electrophysiology [5]. - There is significant untapped international market potential for Beixin Life's products, with plans for deeper internationalization following the IPO [5]. Group 5: Market Context - In 2025, Qiming Venture Partners invested in over 30 projects in the medical innovation sector, contributing more than 3 billion yuan, despite a cautious investment environment in the medical sector [5]. - The firm maintains strong confidence in the fundamentals of Chinese medical innovation, believing that China's clinical experience, engineering teams, and entrepreneurial spirit can foster globally competitive medical device products [6].

红杉中国董事总经理曹弋博（左）与北芯生命创始人、董事长兼CEO宋亮博士在上市仪式 现场。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，深圳北芯生命科技股份有限公司（以下简称"北芯生命"）于2026年2月5日正式 以"688712.SH"为股票代码在上海证券交易所科创板挂牌上市。 值得一提的是， 北芯生命是重启科创板第五套标准后，该标准下第三家、医疗器械行业首家成功上 市企业，也是2024年以来首家在科创板成功上市的医疗器械企业。 作为国内首家拥有血管内功能学血流储备分数（FFR）及影像学血管内超声（IVUS）产品组合的国 产医疗器械公司，北芯生命自成立以来已获得红杉中国等多家知名机构的投资。 其中， 红杉中国于2018年领投了北芯生命的B轮融资且在后续各轮融资中持续支持。IPO前，红杉 中国持有北芯生 命超10%的股份，为公司最大机构投资方，红杉中国董事总经理曹弋博担任北芯生 命董事，也是在北芯生命服务时间最长的投资人董事 曹弋博表示："北芯生命是红杉中国深耕心血管精准诊疗赛道的重要战略布局。我们认为，真正的国 产替代不应止步于复制，而在于超越 ...